# Rigel Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/rigel-pharmaceuticals-inc-x7mhpbcmhfm3

- UEI: X7MHPBCMHFM3
- CAGE: 60TS7
- Location: South San Francisco, CA
- Awards in window: 2 (9 transactions), $0 obligated, February 13, 2024 to May 21, 2026

## Awarding agencies

- Department of Veterans Affairs: 1 awards, $0
- Office of Assistant Secretary for Preparedness and Response: 1 awards, $0

## Industries

- 325412 Pharmaceutical Preparation Manufacturing: $0
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $0

## Competition

- Competed Under SAP: 1 awards
- Full and Open Competition: 1 awards

## Largest awards

- 75A50123C00012 (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. Rigel Pharmaceuticals: the Overall Objective of This Contract Is to Evaluate the Impact of Fostamatinib Treatment During Hospitalization Resulting from Ards on Long-Term Outcomes Including Clinical, Biomarker, Imaging, Qol, Functional and Lung Functi. https://www.usaspending.gov/award/CONT_AWD_75A50123C00012_7505_-NONE-_-NONE-/
- 36F79724D0007: $0, Nac Federal Supply Schedule. Description Change. https://www.usaspending.gov/award/CONT_IDV_36F79724D0007_3600/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/rigel-pharmaceuticals-inc-x7mhpbcmhfm3.